SK15712001A3 - 4,5,6,7-Tetrahydroindazolové deriváty ako protinádorové činidlá - Google Patents

4,5,6,7-Tetrahydroindazolové deriváty ako protinádorové činidlá Download PDF

Info

Publication number
SK15712001A3
SK15712001A3 SK1571-2001A SK15712001A SK15712001A3 SK 15712001 A3 SK15712001 A3 SK 15712001A3 SK 15712001 A SK15712001 A SK 15712001A SK 15712001 A3 SK15712001 A3 SK 15712001A3
Authority
SK
Slovakia
Prior art keywords
indazol
tetrahydro
dimethyl
tetrahydroindazole
alkyl
Prior art date
Application number
SK1571-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Paolo Pevarello
Manuela Villa
Mario Varasi
Antonella Isacchi
Original Assignee
Pharmacia & Upjohn S. P. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn S. P. A. filed Critical Pharmacia & Upjohn S. P. A.
Publication of SK15712001A3 publication Critical patent/SK15712001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1571-2001A 1999-05-12 2000-05-04 4,5,6,7-Tetrahydroindazolové deriváty ako protinádorové činidlá SK15712001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911053.8A GB9911053D0 (en) 1999-05-12 1999-05-12 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
PCT/EP2000/004208 WO2000069846A1 (en) 1999-05-12 2000-05-04 4,5,6,7-tetrahydroindazole derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
SK15712001A3 true SK15712001A3 (sk) 2002-06-04

Family

ID=10853343

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1571-2001A SK15712001A3 (sk) 1999-05-12 2000-05-04 4,5,6,7-Tetrahydroindazolové deriváty ako protinádorové činidlá

Country Status (26)

Country Link
US (1) US6716856B1 (es)
EP (1) EP1177185B1 (es)
JP (1) JP2002544271A (es)
KR (1) KR20010113926A (es)
CN (1) CN1350528A (es)
AR (1) AR023971A1 (es)
AT (1) ATE293618T1 (es)
AU (1) AU4564500A (es)
BR (1) BR0010476A (es)
CA (1) CA2372429A1 (es)
CZ (1) CZ20013970A3 (es)
DE (1) DE60019577T2 (es)
EA (1) EA200101194A1 (es)
ES (1) ES2239595T3 (es)
GB (1) GB9911053D0 (es)
HK (1) HK1045687A1 (es)
HU (1) HUP0201225A3 (es)
IL (1) IL146100A0 (es)
MX (1) MXPA01011441A (es)
NO (1) NO20015477L (es)
NZ (1) NZ514873A (es)
PL (1) PL351611A1 (es)
PT (1) PT1177185E (es)
SK (1) SK15712001A3 (es)
WO (1) WO2000069846A1 (es)
ZA (1) ZA200108530B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60108626T2 (de) 2000-04-25 2005-12-22 Bristol-Myers Squibb Co. Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
JP2004517840A (ja) * 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) * 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
CN1826343A (zh) 2003-05-22 2006-08-30 法玛西雅意大利公司 吡唑并－喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
ES2313317T3 (es) * 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
UA92907C2 (uk) * 2005-02-25 2010-12-27 Серенекс, Інк. Похідні тетрагідроіндазолону
WO2006133634A1 (fr) * 2005-06-14 2006-12-21 Beijing Gylongly Biodemtech Co., Ltd Dérivés tétrahydroindole et dérivés tétrahydroindazole et leur utilisation
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
CN101268048A (zh) * 2005-09-16 2008-09-17 瑟瑞耐克斯有限公司 咔唑衍生物
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP2009532329A (ja) * 2006-02-27 2009-09-10 セレネックス， インコーポレイテッド シクロヘキシルアミノ、ベンゼン、ピリジン及びピリダジン誘導体
ES2442491T3 (es) 2006-03-03 2014-02-11 Nerviano Medical Sciences S.R.L. Biciclopirazoles activos como inhibidores de cinasa
WO2008024974A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Pyrimidine and pyrazine derivatives
US20080076813A1 (en) * 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
WO2008024978A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US20090093452A1 (en) * 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
WO2008024981A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Piperazine-substituted benzothiophenes for treatment of mental disorders
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
ES2546816T3 (es) 2007-02-27 2015-09-28 Nerviano Medical Sciences S.R.L. Isoquinolinpirrolopiridinonas activas como inhibidores de cinasa
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
CN102105148B (zh) 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
CN102282147B (zh) 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102311389A (zh) * 2010-06-29 2012-01-11 王小龙 一种氮芳香取代吡唑衍生物、及其合成和抗癌应用
US8541576B2 (en) 2010-12-17 2013-09-24 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
US8829024B2 (en) 2011-01-07 2014-09-09 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
CA2872933A1 (en) * 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment cancer
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2869172T3 (es) 2013-11-25 2021-10-25 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
CR20220299A (es) 2019-12-20 2022-08-05 Pfizer Derivados de becimidazol
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657438A (en) * 1968-09-27 1972-04-18 Ciba Geigy Corp Compositions and methods for treating inflammation
US3657270A (en) * 1970-01-16 1972-04-18 Parke Davis & Co 1-phenyl-1h-indazole-4-acetic acids
US3691180A (en) * 1970-07-31 1972-09-12 Ciba Geigy Corp Cycloalkano (c)pyrazoles
JPS60130521A (ja) 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
JPS6299361A (ja) 1985-10-25 1987-05-08 Morishita Seiyaku Kk インデノ〔１，２−ｃ〕ピラゾ−ル誘導体
KR880009024A (ko) * 1987-01-27 1988-09-13 게리 디.스트리트 기관지 확장제용 디피라졸
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JP2001518501A (ja) * 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
ATE293618T1 (de) 2005-05-15
EP1177185B1 (en) 2005-04-20
EP1177185A1 (en) 2002-02-06
NO20015477D0 (no) 2001-11-08
EA200101194A1 (ru) 2002-06-27
MXPA01011441A (es) 2002-10-21
BR0010476A (pt) 2003-07-01
HK1045687A1 (zh) 2002-12-06
DE60019577D1 (de) 2005-05-25
KR20010113926A (ko) 2001-12-28
CA2372429A1 (en) 2000-11-23
DE60019577T2 (de) 2006-03-09
AR023971A1 (es) 2002-09-04
AU4564500A (en) 2000-12-05
ES2239595T3 (es) 2005-10-01
US6716856B1 (en) 2004-04-06
WO2000069846A1 (en) 2000-11-23
HUP0201225A2 (en) 2002-08-28
JP2002544271A (ja) 2002-12-24
CZ20013970A3 (cs) 2002-04-17
CN1350528A (zh) 2002-05-22
ZA200108530B (en) 2003-02-03
GB9911053D0 (en) 1999-07-14
PT1177185E (pt) 2005-08-31
PL351611A1 (en) 2003-05-05
NO20015477L (no) 2002-01-11
HUP0201225A3 (en) 2003-11-28
NZ514873A (en) 2004-05-28
IL146100A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
SK15712001A3 (sk) 4,5,6,7-Tetrahydroindazolové deriváty ako protinádorové činidlá
KR101084871B1 (ko) 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
JP5284973B2 (ja) 三環式インドールおよび（４，５−ジヒドロ）インドール
ES2281633T3 (es) Derivados triciclicos de pirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
EP1847532B1 (en) Igf-1r inhibitor
CN106459035B (zh) N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
KR20180066985A (ko) 티에노피리미딘 유도체 및 이의 용도
US20070142414A1 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
SG189086A1 (en) 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists
CA2602303A1 (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
US8119641B2 (en) 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors
JP5303271B2 (ja) キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物
US6720332B2 (en) Oxindole derivatives
Ohashi Discovery of Novel Hedgehog Signaling Inhibitor
大橋知洋 Discovery of Novel Hedgehog Signaling Inhibitor
CN114728965A (zh) 吡啶并杂环类化合物、其制备方法及用途

Legal Events

Date Code Title Description
FC9A Refused patent application